Sutro Biopharma, Inc. (STRO) News
Filter STRO News Items
STRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
STRO News Highlights
- For STRO, its 30 day story count is now at 6.
- Over the past 26 days, the trend for STRO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DRUG are the most mentioned tickers in articles about STRO.
Latest STRO News From Around the Web
Below are the latest news stories about SUTRO BIOPHARMA INC that investors may wish to consider to help them evaluate STRO as an investment opportunity.
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced substantial clinical benefit - - REFRaME-O1, the Phase 2/3 pivotal study of luvelta for patients with platinum-resistant ovarian cancer has been initiated and is open for enrollment - SOUTH SAN FRANCISCO, Cali |
Sutro Biopharma to Participate in the Jefferies Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 4:30 p.m. ET/1:30 p.m. PT in New York City. A webcast of the fireside chat will be accessible through t |
Investors in Sutro Biopharma (NASDAQ:STRO) have unfortunately lost 51% over the last three yearsSutro Biopharma, Inc. ( NASDAQ:STRO ) shareholders should be happy to see the share price up 15% in the last month... |
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue EstimatesSutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 8.43% and 11.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones- Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating properties in preclinical models, suggesting its potential to augment checkpoint blockade therapy - - As of March 31, 2023, Sutro had cash and investments of $251.5 million and shares of Vaxcyte common stock valued at |
Sutro Biopharma to Present at the JMP Securities Life Sciences ConferenceSOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the JMP Securities Life Sciences Conference on Monday, May 15th, 2023, at 2:00 p.m. ET / 11:00 a.m. PT in New York City. The presentation will be accessible through the News & Events page of th |
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseSutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific OfficerSOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the Company’s President of Research & Chief Scientific Officer, Trevor Hallam, Ph.D., will be departing from his position effective May 31, 2023 and will immediately join the Company’s Scientific Advisory Board. “On behalf of Sutro, we would like to |